PMID- 26917816
OWN - NLM
STAT- MEDLINE
DCOM- 20161027
LR  - 20221207
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 50
IP  - 5
DP  - 2016 May
TI  - Ranolazine and Its Effects on Hemoglobin A1C.
PG  - 410-5
LID - 10.1177/1060028016631757 [doi]
AB  - OBJECTIVE: To review the antihyperglycemic effect of ranolazine in type 2 
      diabetes mellitus (T2DM). DATA SOURCES: An EMBASE search was conducted between 
      January 1966 through December 2015 using the search termsranolazine, diabetes, 
      andhemoglobin A1C(A1C). Additional references were identified from a review of 
      literature citations. A search of clinicaltrials.gov was conducted to identify 
      unpublished studies assessing ranolazine in diabetes. STUDY SELECTION AND DATA 
      EXTRACTION: All English-language observational and randomized controlled trials 
      assessing the effects of ranolazine on A1C were evaluated. DATA SYNTHESIS: Four 
      published and 3 unpublished trials were identified. In all except 1 study, 
      ranolazine 750 to 1000 mg twice daily was associated with a statistically 
      significant decrease in A1C compared with placebo (placebo-corrected change in 
      A1C: -0.28 to -0.7). In the trial in which a significant difference was not 
      observed, patients assigned to ranolazine received a lower maintenance metformin 
      dose compared with patients not assigned to ranolazine. A greater percentage of 
      patients randomized to ranolazine achieved an A1C<7% compared with the placebo 
      group (41.2%-59% vs 25.7%-49%). Ranolazine was not associated with an increase in 
      the incidence of hypoglycemia and was well tolerated overall. The mechanism for 
      lowering of A1C has not been determined. CONCLUSIONS: Ranolazine therapy may 
      decrease A1C among patients with T2DM without an increase in hypoglycemia. For 
      patients with T2DM and chronic stable angina, ranolazine may be of use given its 
      utility in cardiovascular disease and benefit in A1C lowering.
CI  - (c) The Author(s) 2016.
FAU - Greiner, Lindsey
AU  - Greiner L
AD  - Veterans Affairs Ann Arbor Healthcare System, MI, USA lindsey.greiner@gmail.com.
FAU - Hurren, Kathryn
AU  - Hurren K
AD  - Veterans Affairs Ann Arbor Healthcare System, MI, USA.
FAU - Brenner, Michael
AU  - Brenner M
AD  - Veterans Affairs Ann Arbor Healthcare System, MI, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160225
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - A6IEZ5M406 (Ranolazine)
SB  - IM
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Glycated Hemoglobin/*analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ranolazine/*therapeutic use
OTO - NOTNLM
OT  - antihyperglycemics
OT  - cardiovascular drugs
OT  - diabetes
OT  - drug information
OT  - drug trials
OT  - hemoglobin A1C
OT  - literature evaluation
OT  - ranolazine
OT  - type 2
EDAT- 2016/02/27 06:00
MHDA- 2016/11/01 06:00
CRDT- 2016/02/27 06:00
PHST- 2016/02/27 06:00 [entrez]
PHST- 2016/02/27 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - 1060028016631757 [pii]
AID - 10.1177/1060028016631757 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2016 May;50(5):410-5. doi: 10.1177/1060028016631757. Epub 2016 
      Feb 25.